AU2003210447B2 - Nitric oxide donors for treatment of disease and injury - Google Patents

Nitric oxide donors for treatment of disease and injury Download PDF

Info

Publication number
AU2003210447B2
AU2003210447B2 AU2003210447A AU2003210447A AU2003210447B2 AU 2003210447 B2 AU2003210447 B2 AU 2003210447B2 AU 2003210447 A AU2003210447 A AU 2003210447A AU 2003210447 A AU2003210447 A AU 2003210447A AU 2003210447 B2 AU2003210447 B2 AU 2003210447B2
Authority
AU
Australia
Prior art keywords
cells
rats
sildenafil
brain
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2003210447A
Other languages
English (en)
Other versions
AU2003210447A1 (en
Inventor
Michael Chopp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Henry Ford Health System
Original Assignee
Henry Ford Health System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henry Ford Health System filed Critical Henry Ford Health System
Publication of AU2003210447A1 publication Critical patent/AU2003210447A1/en
Application granted granted Critical
Publication of AU2003210447B2 publication Critical patent/AU2003210447B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2003210447A 2002-01-04 2003-01-06 Nitric oxide donors for treatment of disease and injury Ceased AU2003210447B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34547802P 2002-01-04 2002-01-04
US60/345,478 2002-01-04
PCT/US2003/000323 WO2003056899A2 (en) 2002-01-04 2003-01-06 Nitric oxide donors for treatment of disease and injury

Publications (2)

Publication Number Publication Date
AU2003210447A1 AU2003210447A1 (en) 2003-07-24
AU2003210447B2 true AU2003210447B2 (en) 2008-02-07

Family

ID=23355218

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003210447A Ceased AU2003210447B2 (en) 2002-01-04 2003-01-06 Nitric oxide donors for treatment of disease and injury

Country Status (9)

Country Link
US (2) US20050143388A1 (enExample)
EP (1) EP1469852A4 (enExample)
JP (2) JP4545440B2 (enExample)
CN (1) CN1638775A (enExample)
AU (1) AU2003210447B2 (enExample)
CA (1) CA2471147C (enExample)
IL (1) IL162850A0 (enExample)
WO (1) WO2003056899A2 (enExample)
ZA (1) ZA200405507B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1909793A2 (de) * 2005-07-15 2008-04-16 Proxomed Medizintechnik GmbH Verwendung von phosphodiesterase typ 5-hemmern für die prävention und behandlung von erkrankungen oder gesundheitsstörungen, sowie abgabesysteme für dieselben
WO2008020864A2 (en) * 2005-11-14 2008-02-21 The Trustees Of Columbia University In The City Of New York Imaging correlates of neurogenesis with mri
US8841300B2 (en) 2006-10-02 2014-09-23 Jerry M. Held Treatment for Parkinson's disease—combination high dose serotonergic synaptic reuptake inhibitor with phosphodiesterase inhibitor
JP2010527928A (ja) * 2007-05-18 2010-08-19 ヴィヴァス・インコーポレイテッド ホスホジエステラーゼ−５阻害剤を含む新規の組み合わせおよびそれらの使用
US20110104100A1 (en) * 2007-10-04 2011-05-05 Medistem Laboratories, Inc. Compositions and methods of stem cell therapy for autism
WO2009059271A1 (en) * 2007-11-02 2009-05-07 University Of Miami Diagnosis and treatment of cardiac disorders
MX361539B (es) 2012-04-25 2018-12-10 Takeda Pharmaceuticals Co Compuesto heterociclico nitrogenado.
EP2873669A4 (en) 2012-07-13 2015-11-25 Takeda Pharmaceutical HETEROCYCLIC CONNECTION
JP6338601B2 (ja) * 2013-03-01 2018-06-06 フンダシオン パラ ラ インベスティガシオン メディカ アプリカダ ホスホジエステラーゼとヒストンデアセチラーゼの二重阻害剤としての新規な化合物
EP2975031A4 (en) 2013-03-14 2017-04-19 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2015002231A1 (ja) 2013-07-03 2015-01-08 武田薬品工業株式会社 複素環化合物
US10472376B2 (en) 2013-07-03 2019-11-12 Takeda Pharmaceutical Company Limited Amide compound
US10297661B2 (en) * 2017-06-30 2019-05-21 Taiwan Semiconductor Manufacturing Co., Ltd. High voltage resistor device
TWI879058B (zh) * 2023-08-31 2025-04-01 未來新藥股份有限公司 Pde5抑制劑組合於促進神經突生長之新穎用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6075028A (en) * 1999-09-23 2000-06-13 Graham; Richard Method of treating Tourette's syndrome and related CNS disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2187086A1 (en) * 1994-04-15 1995-10-26 Masaomi Iyo A pharmaceutical composition for therapeutically treating tardive dyskinesia and uses therof
US5827740A (en) * 1996-07-30 1998-10-27 Osiris Therapeutics, Inc. Adipogenic differentiation of human mesenchymal stem cells
EP1006798A4 (en) * 1996-09-05 2003-03-05 Massachusetts Inst Technology COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISORDERS AND NEURODEGENERATIVE DISEASES
US6043223A (en) * 1997-11-12 2000-03-28 The Regents Of The University Of California Enhanced opening of abnormal brain tissue capillaries
DE19834507A1 (de) * 1998-07-31 2000-02-03 Hexal Ag Pharmazeutische, wasserlösliche Tablettenformulierung zur Anwendung von Sildenafil
DK1183035T3 (en) 1999-05-14 2015-03-09 Ford Henry Health System BONE MARROW TRANSPLANT TREATMENT stroke
NZ516513A (en) * 1999-06-14 2004-03-26 Ford Henry Health System Nitric oxide donors for inducing neurogenesis
IL139073A0 (en) * 1999-10-21 2001-11-25 Pfizer Treatment of neuropathy
US6271228B1 (en) * 2000-04-28 2001-08-07 Pfizer Inc. Blood pressure stabilization during hemodialysis
EP1355669B1 (en) * 2000-08-10 2011-09-28 Cold Spring Harbor Laboratory Augmented cognitive training

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6075028A (en) * 1999-09-23 2000-06-13 Graham; Richard Method of treating Tourette's syndrome and related CNS disorders

Also Published As

Publication number Publication date
CA2471147C (en) 2010-08-10
ZA200405507B (en) 2005-05-25
CA2471147A1 (en) 2003-07-17
EP1469852A2 (en) 2004-10-27
JP4545440B2 (ja) 2010-09-15
JP2009256374A (ja) 2009-11-05
WO2003056899A2 (en) 2003-07-17
WO2003056899A3 (en) 2003-11-27
AU2003210447A1 (en) 2003-07-24
EP1469852A4 (en) 2009-12-02
WO2003056899A9 (en) 2004-04-15
US20050143388A1 (en) 2005-06-30
CN1638775A (zh) 2005-07-13
US20120009152A1 (en) 2012-01-12
JP2005514406A (ja) 2005-05-19
IL162850A0 (en) 2005-11-20

Similar Documents

Publication Publication Date Title
US20120009152A1 (en) Nitric oxide donors for treatment of disease and injury
US9394520B2 (en) Expansion of hematopoietic stem cells
US7514261B2 (en) Platelet-derived growth factor protection of cardiac myocardium
US7658951B2 (en) Method of improving cardiac function of a diseased heart
MXPA04006771A (es) Materiales de celulas estromaticas de medula osea para uso en la formacion de vasos sanguineos y en la produccion de factores angiogenicos y troficos.
JP2004529916A (ja) パーキンソン病の治療において神経栄養活性化合物と組み合わせたアデノシンａ２ａレセプターアンタゴニスト
JP4750416B2 (ja) 副甲状腺ホルモン受容体の活性化と造血前駆細胞の増殖
JP5500773B2 (ja) 副甲状腺ホルモン受容体の活性化並びに幹細胞及び前駆細胞の増殖
US20250009936A1 (en) Tissue regeneration with in vitro activated effector cells
KR102622408B1 (ko) Opa1 억제에 의한 조골세포 활성화를 통한 골형성 촉진 유도용 또는 골질환 치료용 조성물
JP2004123679A (ja) 好酸球カチオン性タンパク質を含有する組成物
CA3168806A1 (en) Therapeutic exosomes and method of producing them
AU2002339944A1 (en) Cardiac transplantation of stem cells for the treatment of heart failure
AU2002332486A1 (en) Platelet-derived growth factor protection of cardiac myocardium

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired